ArticleJournal of molecular histology2025
lncRNA TMEM147-AS1 promotes acute myeloid leukemia development by regulating miR-873-3p/ZFX axis.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Extracellular vesicles-derived non-coding RNA in leukemias and pre-leukemic syndromes: a systematic review.Journal of cancer research and clinical oncology · 2025Pooled it
- Potential regulation mechanism of lncRNA OIP5-AS1 influencing prognosis in acute myeloid leukemia patients via the miR-15a-5p/FOXO1 axis.Journal of molecular histology · 2026Article
- MiR-874-3p suppresses TNF-α-induced inflammation in adipocytes by targeting nucleolin.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous malignancy originating from prolonged abnormal proliferation of immature myeloid cells. Long non-coding RNAs (lncRNAs) are important regulators of AML progression. TMEM147-AS1 has been reported to be abnormally expressed in AML. This study aimed to further explore the roles of TMEM147-AS1 in AML and the possible mechanism. The expression of TMEM147-AS1 and miR-873-3p and its role in the clinical progression of AML were investigated. The diagnostic and prognostic value of TMEM147-AS1 in AML was assessed. The impacts of TMEM147-AS1 on AML cell function were examined. And the targeting relationship among TMEM147-AS1, miR-873-3p, and ZFX was predicted by databases and verified by dual-luciferase reporter assay. TMEM147-AS1 was upregulated in AML tissues and cell lines. High TMEM147-AS1 expression was significantly related to adverse karyotype, shorter overall survival time, and worse prognosis in AML patients. And TMEM147-AS1 can distinguish AML patients from healthy individuals with relatively high sensitivity and specificity. Furthermore, TMEM147-AS1 targeted miR-873-3p, which further targeted ZFX. TMEM147-AS1 promoted proliferation and inhibited apoptosis of AML cells through downregulating the inhibitory effect of miR-873-3p on ZFX expression. TMEM147-AS1 promotes AML progression via regulating the miR-873-3p/ZFX axis. TMEM147-AS1 is a promising diagnostic and prognostic indicator in AML.
Indexed as
Identifiers
41055764What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.